ATG-010 (selinexor) completed the first recurring incurable external weekly T and NK/T cell lymphoma patients.

On September 14, Deqi Pharmaceuticals announced that the oral selective nuclear output inhibitor ATG-010 (selinexor) has completed its first phase I clinical trial (code name: TOUCH) in China for patients with recurring incurable external T-cell lymphoma (PTCL) and NK/T-cell lymphoma (NKTL).
the trial was designed to assess the safety, toerability, and initial efficacy of ATG-010 (selinexor) single-drug maintenance therapy in patients with recurring recurring incurable PTCL and NKTL who had received at least one line of treatment in the past.
T-cell lymphoma and NK/T-cell lymphoma are lymphocytes derived from T-cells and NK cell line, and there are significant regional differences in disease distribution.
PTCL accounts for about 25-30% of non-Hodgkin's lymphoma (NHL) in China.
NKTL is closely related to Epstein-Barr virus infection, which accounts for about 6.4 percent of China's NHL and 24.91 percent of T-cell NHL.
PTCL and NKTL are significantly higher in China's NHL than in Europe and the United States.
at present, first-line chemotherapy programs based on cyclocycline and mendonamidease have limited efficacy for PTCL and NKTL, and there is no standard second-line treatment for patients with relapse or recurring treatment.
ATG-010 (selinexor) is an oral, selective nuclear output inhibitor that causes in-nucleus retention and resuspension of tumor suppressor and other growth-regulating proteins, as well as the reduction of a variety of carcinogenic proteins, and induces apoptosis of large numbers of solid and blood tumor cells in vitro and in vivo, while normal cells are not affected.
clinical studies have shown that ATG-010 (selinexor) is effective and safe for a variety of hematomas and solid tumors.
"PTCL and NKTL are highly heterogeneic and invasive, and existing treatment options are ineffective and have poor prognosis, so there are still a large number of unsecured clinical needs for patients with relapses, especially for patients with multiple comorganisms that are not suitable for transplantation, and there is an urgent need to develop new therapies."
"Clinical trials have shown that ATG-010 single-drug therapy is effective for solid and hematomas and has significant synergies with a variety of chemotherapy and targeted therapies," said Dr. Jianming Mei, founder, chairman and CEO of Deji Pharmaceuticals.
through a combination of companies and complementary clinical strategies, ATG-010 promises to bring a new and effective treatment to this group of patients.
" about ATG-010ATG-010 (selinexor) is the first and only oral selective nuclear output protein inhibitor (SINE) of its kind, for Deki Pharmaceuticals and Karyopharm Therapeutics Inc. (Nasdaq: KPTI) co-develops products.
U.S. Food and Drug Administration FDA approved the treatment of refractic multiple myeloma adaptation (R/R MM) in July 2019 in July 2019, and the treatment of refractic recurring large B-cell lymphoma (R/R DLBCL) in June 2020.
, the ATG-010 (selinexor) is the first and only FDA-approved SINE compound.
Deqi Pharmaceuticals is conducting a phase II registered clinical study in China on ATG-010 (selinexor) treatment of refractic multiple myeloma and refractic recurring large B-cell lymphoma, and has initiated clinical trials for high-risk tumors in the Asia-Pacific region, including T-cell lymphoma and KRAS mutation non-small cell lung cancer (NSCLC).
About Deki Pharmaceuticals Deqi Pharmaceuticals is an integrated biopharmaceutical company with a global distribution of new drugs, clinical research, drug production and marketing, focusing on innovative anti-tumor therapies that provide cutting-edge new mechanisms of action for patients in China and other asia-Pacific countries and regions, as well as around the world.
Since its official operation in April 2017, Deqi Pharmaceuticals has established a rich product pipeline with 12 clinical and preclinically innovative drugs, obtained 9 clinical approvals, and conducted 9 cross-regional clinical trials throughout the Asia Pacific region.
companies focus on innovative targets or mechanisms of action in their research products, with the best potential to be the first of its kind.
Deqi people to "doctors without borders, innovation and sustainability" as the vision, and strive to solve the world's first and the best of the same kind of specialized research and marketization, to solve the Asia-Pacific and even the world's unseeded clinical needs of patients.
Medicine Rubik's Cube Source: !-- Of the !-- Content Display Ends.